Daniel Day - Foundation Medicine Director
Director
Mr. Daniel O Day serves as a member of our Board of Directors of the company .Mr. ODay has served as chief executive officer of Roche Pharmaceuticals since September 2012 and is a member of the Roche corporate executive committee. Mr. ODay has nearly three decades of operating expertise at Roche having served previously in various executive leadership positions for Roche Pharmaceuticals and Diagnostics. Most recently, between January 2010 and August 2012, Mr. ODay served as chief operating officer of Roches Diagnostics Division. He also serves on the board of directors of Flatiron Health, Inc., Roche Pharma AG, Shanghai Roche Pharmaceuticals Ltd., Genentech and Chugai Pharmaceutical Co., Ltd. He served on the board of directors of Genentech USA, Inc. from August 2012 to December 2013 and Roche Diagnostics GmbH from January 2010 to November 2012 since 2015.
| Age | 52 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 617 418-2200 |
| Web | www.foundationmedicine.com |
Foundation Medicine Management Efficiency
Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Larson | Fomento Economico Mexicano | 61 | |
| Gary Fayard | Genuine Parts Co | 69 | |
| Paulina Marroquin | Fomento Economico Mexicano | 48 | |
| Ricardo Escajadillo | Fomento Economico Mexicano | 67 | |
| Paul Finnegan | CDW Corp | 65 | |
| Jenner Wood | Genuine Parts Co | 66 | |
| Max Gonzalez | Fomento Economico Mexicano | 49 | |
| Jose Rojas | Fomento Economico Mexicano | 66 | |
| Philip Maritz | Asbury Automotive Group | 60 | |
| Sean Cary | Willamette Valley Vineyards | 40 | |
| Donna Hyland | Genuine Parts Co | 60 | |
| Joel Alsfine | Asbury Automotive Group | 51 | |
| Sydney Selati | Monster Beverage Corp | 78 | |
| Benjamin Polk | Monster Beverage Corp | 66 | |
| CPA JD | Willamette Valley Vineyards | 77 | |
| Mary Bullock | Genuine Parts Co | 70 | |
| Craig Smith | Willamette Valley Vineyards | 67 | |
| Max Suberville | Fomento Economico Mexicano | 82 | |
| Molses Naim | Fomento Economico Mexicano | 65 | |
| Robert Denham | Fomento Economico Mexicano | 75 | |
| Bridget RyanBerman | Asbury Automotive Group | 60 | |
Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 |
Foundation Medicine Leadership Team
Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Day, Director | ||
| Michael Varney, Director | ||
| Krishna Yeshwant, Independent Director | ||
| David Daly, Chief Commercial Officer | ||
| David Schenkein, Independent Director | ||
| Melanie Nallicheri, Chief business Officer and head of Biopharma | ||
| Alexis Borisy, Chairman of the Board, Co-Founder | ||
| Steven Kafka, Pres and COO | ||
| Evan Jones, Independent Director | ||
| Vincent Miller, Chief Medical Officer | ||
| Konstantin Fiedler, COO | ||
| Michael Pellini, President CEO, Director | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Sandra Horning, Director | ||
| Michael Doherty, Head of Product Development | ||
| Jason Ryan, CFO | ||
| Michael Dougherty, Director | ||
| Tom Civik, Chief Commercial Officer | ||
| Troy Cox, CEO, Director | ||
| Thomas Civik, Chief Commercial Officer |
Foundation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (83.98) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 37.14 M | |||
| Shares Owned By Insiders | 58.74 % | |||
| Shares Owned By Institutions | 36.24 % | |||
| Number Of Shares Shorted | 2.35 M | |||
| Price To Earning | (9.70) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Foundation Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Foundation Medicine's short interest history, or implied volatility extrapolated from Foundation Medicine options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Foundation Stock
If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |